LightNews LightNews
mettlercamille.bsky.social
@mettlercamille.bsky.social
11 followers 38 following 1 posts
Posts Replies Media Videos
Reposted
mettlercamille.bsky.social
Congrats to Dr. Pallotti & Prof. @terrierben.bsky.social on their collaborative work exploring the overlapping forms of #GPA and #EGPA, made possible through European teamwork! 🎉 #Research #Collaboration #GFEV #AAV
December 11, 2025 at 9:25 PM
mettlercamille.bsky.social
Congrats to Dr. Pallotti & Prof. @terrierben.bsky.social on their collaborative work exploring the overlapping forms of #GPA and #EGPA, made possible through European teamwork! 🎉 #Research #Collaboration #GFEV #AAV
December 11, 2025 at 9:25 PM
Reposted
jinternmed.bsky.social
New article to read! Overlapping forms of #granulomatosis with #polyangiitis and #eosinophilic granulomatosis with polyangiitis.

➡️ Insights from a European multicenter study
➡️ Underscores the need for personalized treatment approaches

🔗 doi.org/10.1111/joim.70056
<em>Journal of Internal Medicine</em> | Wiley Online Library
Background Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) are distinct forms of antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV)....
doi.org
December 10, 2025 at 8:09 AM
Reposted
nejm.org
In the VAYHIT2 phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. Full trial results: nej.md/49OeoGf
67th ASH Annual Meeting Original Article | Dec. 9, 2025 | NEJM.org Ianalumab plus Eltrombopag in Immune Thrombocytopenia (VAYHIT2) Figure 2. Kaplan–Meier Estimates of the Primary End Point. The NEJM identity sits at the bottom.
December 9, 2025 at 12:35 PM
Reposted
jama.com
The most common chronic liver disease worldwide, metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 30% to 40% of the general adult population.

This Review summarizes the diagnosis, treatment, and prognosis of MASLD. ja.ma/3XiORgN
Figure outlines MASLD progression from healthy liver to cirrhosis/hepatic decompensation. Factors promoting MASLD include diet, insulin resistance; protective factors: physical exercise, socioeconomic status. Progression rates are shown. Text: JAMA, Published online November 10, 2025.
November 10, 2025 at 4:30 PM
Reposted
jama.com
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that predominantly affects women ages 40 to 60 years.

💡 This JAMA Insights discusses the clinical presentation, diagnosis, and treatment of PBC.

ja.ma/43T7yeF
Published online November 10, 2025, JAMA Insights, Primary Biliary Cholangitis, by Michele M. Tana, MD, MHS; Gideon M. Hirschfield, MA, MBBChir, PhD. Figure. Primary Biliary Cholangitis (PBC)—From Diagnosis to Personalized Care.
November 10, 2025 at 5:15 PM
Reposted
revmedinterne.bsky.social
ℹ️ Mise au point
Prise en charge d’une leucémie aiguë et de ses complications à la phase initiale : c’est à retrouver dans la Revue ce mois-ci 👇

www.sciencedirect.com/science/arti...
November 4, 2025 at 12:08 PM
Reposted
jama.com
📊 JAMA Guide to Statistics and Methods:

Pattern-mixture models allow researchers to systematically vary assumptions about missing trial data and examine whether biases due to nonrandom missingness could undermine study findings.

ja.ma/49oqsxC
An article titled "Pattern-Mixture Models for Missing Data" by Roderick J. Little, PhD, from JAMA Guide to Statistics and Methods. Published online October 30, 2025. The article discusses missing data in clinical trials and methods to address it.
October 30, 2025 at 3:45 PM
Reposted
jama.com
Uveitis is a condition involving inflammation in the uvea (the middle portion of the eye).

📝 This JAMA Patient Page describes types of uveitis, ages and conditions associated with uveitis, and diagnosis and treatment.

ja.ma/48TW7a4
Diagram explaining uveitis, an eye inflammation. It shows eye anatomy, uveitis types (anterior, intermediate, posterior, panuveitis), associated symptoms like redness and pain, and treatments including antibiotics and steroid eye drops. Untreated uveitis may cause vision loss.
October 30, 2025 at 4:00 PM
Reposted
natrevrheum.nature.com
Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis
Nature Reviews Rheumatology, Published online: 16 October 2025; doi:10.1038/s41584-025-01306-wANCA-associated vasculitis (AAV) includes three disease subtypes with partly overlapping clinical manifestations: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). This Review article provides an update on the diagnosis and classification of AAV, discussing parameters for assessing disease activity and predicting outcomes towards a personalized medicine approach.
bit.ly
October 16, 2025 at 3:30 PM
Reposted
jama.com
Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years.

Learn more about the epidemiology, pathophysiology, diagnosis, and treatment of uveitis in this review.

https://ja.ma/44qBqyA
Figure 2. Uveitis Pathogenesis
July 4, 2025 at 12:00 PM
Reposted
natrevrheum.nature.com
New content online:
Arterial and venous thrombosis in systemic and monogenic vasculitis
Nature Reviews Rheumatology, Published online: 06 May 2025; doi:10.1038/s41584-025-01252-7Systemic vasculitis, including monogenic forms, is associated with an increased risk of arterial and venous thromboembolic events (AVTEs). This Review highlights the latest advances in the understanding of the pathogenesis, clinical features and management of AVTEs in systemic and monogenic vasculitis.
bit.ly
May 6, 2025 at 5:32 PM
Reposted
nejm.org
Intention-to-treat analyses may be diluted by noncompliance, while per-protocol analyses have selection bias. Instrumental variables methods may solve both problems. Angrist and colleagues discuss instrumental variables estimation in #ClinicalTrials. 👉 eviden.cc/4kLNGRM

#MedSky
A figure showing simple instrumental variables estimates of the effect of revascularization on year 1 Seattle Angina Questionnaire Quality of Life Score.
May 7, 2025 at 1:04 PM
Reposted
nejm.org
Our partnership with @glaucomflecken.bsky.social continues as he summarizes new research into fracture prevention with infrequent zoledronate in women 50 to 60 years of age. Access the article for free: nej.md/DrG15

#MedSky
April 22, 2025 at 7:03 PM
Reposted
nejm.org
In the REGENCY phase 3 trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results and Research Summary: nej.md/3Eq6gxV

#MedSky
The New England Journal of Medicine Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis A Research Summary based on Furie RA et al. | 10.1056/NEJMoa2410965 | Published on February 7, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
April 20, 2025 at 7:01 PM
Reposted
revmedinterne.bsky.social
Human papillomavirus et lupus systémique : une revue systématique
www.sciencedirect.com/science/arti...
#SLE #HPV
March 23, 2025 at 8:55 PM
Reposted
jama.com
The risk of venous thromboembolism (VTE) varies across contemporary hormonal contraceptives, with the highest risk associated with combined pills.

#MedSky https://ja.ma/3Y5WQPf
Contemporary Hormonal Contraception and Risk of Venous Thromboembolism
This study assesses the risk of venous thromboembolism of different forms of hormonal contraception, including pills with estrogen and progestin, vaginal rings, patches, progestin-only pills, intrauterine devices, implants, and injections.
ja.ma
April 18, 2025 at 6:00 PM